Compare HHH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHH | MIRM |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | HHH | MIRM |
|---|---|---|
| Price | $80.34 | $79.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $90.00 | ★ $92.45 |
| AVG Volume (30 Days) | 394.3K | ★ 809.5K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 234.52 | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $1,834,033,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $19.38 | $19.91 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | ★ 69.81 | 53.66 |
| 52 Week Low | $61.41 | $36.88 |
| 52 Week High | $91.07 | $82.58 |
| Indicator | HHH | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 63.35 |
| Support Level | $77.47 | $77.99 |
| Resistance Level | $80.86 | $82.58 |
| Average True Range (ATR) | 1.84 | 3.21 |
| MACD | -0.40 | 1.07 |
| Stochastic Oscillator | 28.07 | 86.72 |
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.